29397 Agoura Road, Suite 107
37 articles with Oncotelic Inc.
Oncotelic Announces the launch of PDAO token
Oncotelic Therapeutics, Inc announced the launch of Pet2DAO Inc., a wholly owned subsidiary of Oncotelic, and its associated token PDAO.
Oncotelic Issues Year End Message to Shareholders - December 28, 2022
Oncotelic Therapeutics, Inc, a clinical stage cancer and aging biotechnology company, issued a letter to its shareholders from its Chief Executive Officer, Dr. Vuong Trieu.
Oncotelic Presents Clinical Data of Confirming TGF-β2 as the appropriate target for gliomas at JCA-AACR Meeting 2022
Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage biotechnology company, today announced today announced it presented new clinical confirming TGF-β2 as the appropriate target for gliomas at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research— Translating Knowledge into Practice December 10 - 14, 2022.
Oncotelic Publishes SITC Meeting 2022 Presentation Materials
Oncotelic Therapeutics, Inc, a developer of treatments for rare and orphan indications, including Parkinson’s Disease, PDAC, DIPG, and COVID-19, announced the publication of the presentation materials from SITC 37th annual meeting held in Boston, MA on November 10th-12th, 2022 on our website.
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas
Oncotelic Therapeutics, Inc today announced that it has submitted a clinical study protocol to the US Food and Drug Administration (“FDA”) for the initiation of a Phase 1 Trial (designated "G101") for OT-101, the Company's transforming growth factor beta 2 (“TGF-β2”) inhibitor, as a treatment for patients with recurrent/relapsed DMG.
Oncotelic Announces Formation of Animal Health Division
Oncotelic Therapeutics, Inc, directly and / or through its wholly owned subsidiaries Oncotelic Inc. and PointR Data Inc., a developer of treatments for rare and orphan indications, including Parkinson’s Disease, PDAC, DIPG, and COVID-19, announced the formation of an animal health division.
Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting
Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) ( OTCQB:OTLC ), developer of treatments for rare and orphan indications, including Parkinson Disease, Pancreatic Cancer, and DIPG, today announced that the Company will be presenting at the upcoming SITC 37th Annual Meeting, held November 10-12, 2022, in Boston, MA.
Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
Oncotelic Therapeutics, Inc. today announced that the Company will have two poster presentations at the upcoming 2022 Society for Neuro-Oncology (SNO) Annual Meeting on November 16-20, 2022, Tampa Bay, Florida.
Oncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancer
Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that the Company presentation at 7th JCA-AACR Special Joint Conference (July 8-10, 2022) is now available at https://www.oncotelic.com/wp-content/uploads/2022/07/JCA-2022.pptx.pdf and https://www.youtube.com/watch?v=D9h7ExvUUVs .
Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention
Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that the Company presentation at BIO International Convention is now available at https://www.oncotelic.com/wp-content/uploads/2022/06/BIO-2022-digital-slides.pdf .
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)
Oncotelic Therapeutics, Inc. today announced the clearance of the Phase 2 clinical trial protocol for mesothelioma after filing the protocol to the Food and Drug Administration.
Oncotelic Announces Pipeline Presentation and IPO Update of Sapu Therapeutics at the 2022 BIO International Convention
Oncotelic Therapeutics, Inc. announced the Company will be presenting at the BIO International Convention taking place in San Diego, California between June 13 - 16, 2022.
ONCOTELIC ANNOUNCES US PATENT GRANT FOR CA4P AND OXI4503 COMBINATION WITH CHECKPOINT INHIBITORS
Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), is pleased to announce the grant of patent application no. 15/753,882 entitled “USE OF VDAS TO ENHANCE IMMUNOMODULATING THERAPIES AGAINST TUMORS” by the US Patent Office.
Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory Officer
Oncotelic Therapeutics, Inc. today announced the appointment of Dr. Seymour Fein as its Chief Regulatory Officer.
Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical Officer
Oncotelic Therapeutics, Inc., announced the appointment of Dr. Fatih Uckun as its Chief Medical Officer.
Oncotelic Provides Ye 2021 Financial Results Compared To Ye 2020, Product Developmet Initiatives And Corporate Update
OncotelicTherapeutics, Inc. announced financial results for the full year ended December 31, 2021 as compared to the full year ended December 31, 2020, an update on its product and therapeutic development initiatives and other corporate updates.
Dr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summit
Oncotelic Therapeutics, Inc. and Marcus Evans are proud to announce Dr Anthony E. Maida, Chief Clinical Officer – Translational Medicine for Oncotelic, Inc. as a speaker at the upcoming annual Evolution Summit taking place in Los Angeles this month.
Clinical Catch-Up: January 3-7
1/10/2022The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.
ONCOTELIC ANNOUNCES THAT ORF8 MUTATIONS ARE DRIVING THE EVOLUTION OF THE DELTA AND THE OMICRON VARIANTS.
Oncotelic Therapeutics, Inc. today announced that it has performed mutational analysis of SARS-CoV-2 and demonstrated that the open reading frames 8 (“ORF8”) is potentially driving the evolution of the Delta and the Omicron variants.